M&A Deal Summary

Essentra Acquires Kamsri Printing & Packaging Pvt.

On October 16, 2015, Essentra acquired packaging company Kamsri Printing & Packaging Pvt.

Acquisition Highlights
  • This is Essentra’s 4th transaction in the Packaging sector.
  • This is Essentra’s 1st transaction in India.

M&A Deal Summary

Date 2015-10-16
Target Kamsri Printing & Packaging Pvt.
Sector Packaging
Buyer(s) Essentra
Deal Type Add-on Acquisition

Target

Kamsri Printing & Packaging Pvt.

Bengaluru, India
Kamsri Printing & Packaging Pvt. Ltd. is a manufacturer of premium packaging solutions for the pharmaceutical and healthcare end-markets in India.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Essentra

Oxford, United Kingdom

Category Company
Founded 2005
Sector Plastics
Employees2,880
Revenue 302M GBP (2024)
DESCRIPTION

Essentra is a provider of essential components and solutions, focusing on the manufacture and distribution of plastic injection moulded, vinyl dip moulded, and metal items. Essentra was founded in 2005 and is based in Oxford, England.


DEAL STATS #
Overall 16 of 21
Sector: Packaging M&A 4 of 5
Type: Add-on Acquisition M&A Deals 15 of 20
Country: India M&A 1 of 1
Year: 2015 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-12-11 Clondalkin - Packaging Division

Amsterdam, Netherlands

Clondalkin has two facilities in Ireland, a site in Dublin used to make fine paper for office and commercial printing use and a factory in Cork that is a major supplier and manufacturer of packaging materials for the pharmaceutical and medical device sectors. Clondalkin’s speciality packaging division, which has 24 sites in total.

Buy $455M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-25 Essentra - Porous Technologies Business

Milton Keynes, United Kingdom

Essentra - Porous Technologies Business products support essiental bio medical procedures such as disease detection and prevention, laboratory testing and genetic analysis.

Sell £220M